108 related articles for article (PubMed ID: 7781699)
1. Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats.
Nakayama K; Murakami N; Ohta M; Kato K; Notsu T; Mizota M; Miwa I; Okuda J
Eur J Pharmacol; 1995 Mar; 276(1-2):85-91. PubMed ID: 7781699
[TBL] [Abstract][Full Text] [Related]
2. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
Nakayama K; Murakami N; Ohta M; Kato K; Ida K; Mizota M; Miwa I; Okuda J
Eur J Pharmacol; 1995 Mar; 276(1-2):77-83. PubMed ID: 7781698
[TBL] [Abstract][Full Text] [Related]
3. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
Kato K; Nakayama K; Ohta M; Murakami N; Murakami K; Mizota M; Miwa I; Okuda J
Eur J Pharmacol; 1991 Feb; 193(2):185-91. PubMed ID: 1828768
[TBL] [Abstract][Full Text] [Related]
5. Acceleration of glycolysis in erythrocytes by the antidiabetic agent M16209.
Hashimoto K; Murakami N; Ohta M; Kato K; Mizota M; Miwa I; Okuda J
Biol Pharm Bull; 1996 Jun; 19(6):809-13. PubMed ID: 8799477
[TBL] [Abstract][Full Text] [Related]
6. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Portha B; Serradas P
Am J Med; 1991 Jun; 90(6A):15S-21S. PubMed ID: 1831320
[TBL] [Abstract][Full Text] [Related]
7. Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats.
Ohta M; Murakami N; Kato K; Mizota M; Miwa I; Okuda J; Yoshimasa Y; Kuzuya H; Nakao K; Imura H
Metabolism; 1996 Sep; 45(9):1095-100. PubMed ID: 8781296
[TBL] [Abstract][Full Text] [Related]
8. Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3-L1 adipocytes.
Murakami N; Inoue G; Okamoto M; Yoshimasa Y; Kohno S; Hayashi T; Kato K; Kuzuya H; Nakao K
Life Sci; 1997; 60(20):1821-31. PubMed ID: 9150422
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent.
Murakami N; Ohta M; Hashimoto K; Kato K; Mizota M; Miwa I; Okuda J; Inoue G; Kuzuya H; Nakao K; Imura H
Eur J Pharmacol; 1996 May; 304(1-3):129-34. PubMed ID: 8813594
[TBL] [Abstract][Full Text] [Related]
10. Insulin-secretagogue activity of p-methoxycinnamic acid in rats, perfused rat pancreas and pancreatic beta-cell line.
Yibchok-anun S; Adisakwattana S; Moonsan P; Hsu WH
Basic Clin Pharmacol Toxicol; 2008 May; 102(5):476-82. PubMed ID: 18346054
[TBL] [Abstract][Full Text] [Related]
11. Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.
Kato K; Nakayama K; Ohta M; Murakami N; Murakami K; Mizota M; Miwa I; Okuda J
Jpn J Pharmacol; 1990 Dec; 54(4):355-64. PubMed ID: 2128352
[TBL] [Abstract][Full Text] [Related]
12. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.
Masiello P; Broca C; Gross R; Roye M; Manteghetti M; Hillaire-Buys D; Novelli M; Ribes G
Diabetes; 1998 Feb; 47(2):224-9. PubMed ID: 9519717
[TBL] [Abstract][Full Text] [Related]
13. Effects of 1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin on human aldose reductase examined by a new application of HPLC system for measuring tissue polyol.
Murakami N; Ohta M; Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
Arzneimittelforschung; 1997 Nov; 47(11):1222-5. PubMed ID: 9428978
[TBL] [Abstract][Full Text] [Related]
14. Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound.
Furukawa N; Ohta T; Noguchi T; Yonemori F; Wakitani K
Eur J Pharmacol; 1999 Apr; 371(1):51-8. PubMed ID: 10355594
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphodiesterase 3B in insulin-secreting cells of normal and streptozocin-nicotinamide-induced diabetic rats: implications for insulin secretion.
Zywert A; Szkudelska K; Szkudelski T
J Physiol Pharmacol; 2014 Jun; 65(3):425-33. PubMed ID: 24930515
[TBL] [Abstract][Full Text] [Related]
16. Insulin treatment improves relative hypersecretion of amylin to insulin in rats with non-insulin-dependent diabetes mellitus induced by neonatal streptozocin injection.
Hiramatsu S; Inoue K; Sako Y; Umeda F; Nawata H
Metabolism; 1994 Jun; 43(6):766-70. PubMed ID: 8201968
[TBL] [Abstract][Full Text] [Related]
17. JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats.
Ohta T; Furukawa N; Komuro G; Yonemori F; Wakitani K
Br J Pharmacol; 1999 Apr; 126(7):1674-80. PubMed ID: 10323602
[TBL] [Abstract][Full Text] [Related]
18. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
19. Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats.
Gedulin B; Cooper GJ; Young AA
Biochem Biophys Res Commun; 1991 Oct; 180(2):782-9. PubMed ID: 1953751
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K1 alleviates streptozotocin-induced type 1 diabetes by mitigating free radical stress, as well as inhibiting NF-κB activation and iNOS expression in rat pancreas.
Varsha MK; Thiagarajan R; Manikandan R; Dhanasekaran G
Nutrition; 2015 Jan; 31(1):214-22. PubMed ID: 25466668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
